Tacrine
Cognex (tacrine) is a small molecule pharmaceutical. Tacrine was first approved as Cognex on 1993-09-09. It is used to treat alzheimer disease in the USA. The pharmaceutical is active against cholinesterase and acetylcholinesterase. In addition, it is known to target muscarinic acetylcholine receptor M2 and muscarinic acetylcholine receptor M1.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Tacrine hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| COGNEX | Shionogi | N-020070 DISCN | 1993-09-09 | 4 products |
Hide discontinued
Labels
FDA
EMA
No data
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| alzheimer disease | EFO_0000249 | D000544 | F03 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| S0014 | Tacrine hydrochloride, 10 mg |
Clinical
Clinical Trials
28 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | 2 | — | — | — | 3 |
| Neoplasms | D009369 | C80 | — | 1 | — | — | 2 | 3 | |
| Squamous cell carcinoma of head and neck | D000077195 | 1 | 1 | — | — | — | 2 | ||
| Pancreatic intraductal neoplasms | D000077779 | — | 1 | — | — | — | 1 | ||
| Myeloid leukemia acute | D015470 | C92.0 | — | 1 | — | — | — | 1 | |
| Melanoma | D008545 | — | 1 | — | — | — | 1 | ||
| Colonic neoplasms | D003110 | C18 | — | 1 | — | — | — | 1 | |
| Rectal neoplasms | D012004 | — | 1 | — | — | — | 1 | ||
| Fragile x syndrome | D005600 | Q99.2 | — | 1 | — | — | — | 1 | |
| Hypertension | D006973 | EFO_0000537 | I10 | — | 1 | — | — | — | 1 |
Show 4 more
Indications Phases 1
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | TACRINE |
| INN | tacrine |
| Description | Tacrine is a member of the class of acridines that is 1,2,3,4-tetrahydroacridine substituted by an amino group at position 9. It is used in the treatment of Alzheimer's disease. It has a role as an EC 3.1.1.7 (acetylcholinesterase) inhibitor. It is a member of acridines and an aromatic amine. It is a conjugate base of a tacrine(1+). |
| Classification | Small molecule |
| Drug class | acridine derivatives |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | Nc1c2c(nc3ccccc13)CCCC2 |
Target
Agency Approved
BCHE
BCHE
ACHE
ACHE
Organism
Homo sapiens
Gene name
BCHE
Gene synonyms
CHE1
NCBI Gene ID
Protein name
cholinesterase
Protein synonyms
Acylcholine acylhydrolase, Butyrylcholine esterase, Choline esterase II, cholinesterase (serum) 2, cholinesterase 1, Pseudocholinesterase
Uniprot ID
Mouse ortholog
Bche (12038)
cholinesterase (Q543J3)
Alternate
CHRM2
CHRM2
CHRM1
CHRM1
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 4,478 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
640 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more